Peptide-loading complex is essential for MHC-I antigen presentation and could be targeted to improve cancer immunotherapy | Research

The takeaway

The peptide-loading complex (PLC) coordinates MHC-I peptide loading in the ER, and tumors evade immunity by downregulating PLC components—restoring PLC function could enhance T cell-based cancer immunotherapy responses.

PLC downregulation = immune evasion
Tumors reduce peptide-loading complex components to hide from immune detection, explaining resistance to checkpoint inhibitors and adoptive T cell therapy

What the researchers found

PLC coordinates MHC-I peptide loading (calreticulin, tapasin, ERp57, TAP). Tumor immune evasion through PLC component downregulation → reduced MHC-I. MHC-I loss → resistance to checkpoint inhibitors and adoptive T cell therapy. Restoring PLC function could overcome immune evasion.

Why it matters

Many cancer patients fail to respond to immunotherapy because their tumors hide from the immune system by reducing MHC-I. Understanding the PLC—the machinery that loads peptides for immune recognition—reveals new therapeutic targets to make tumors visible again.

How the study worked

Narrative review of PLC structure, function, and role in cancer immune evasion and immunotherapy response.

What this study cannot tell us

Narrative review. Most PLC restoration strategies are conceptual. In vivo evidence for therapeutic PLC modulation is limited. Tumor heterogeneity in PLC expression complicates targeting.

How to read the evidence

Narrative review of established PLC biology applied to cancer. Strong conceptual framework but limited therapeutic evidence.

When this study was published

Published in 2025.

The bigger picture

The PLC represents a fundamental bottleneck in anti-tumor immunity. Therapies that restore PLC function could universally enhance cancer immunotherapy across tumor types by forcing tumors to display their antigens.

Questions still open

Can drugs restore PLC component expression in tumors?
Would PLC-targeted therapy synergize with checkpoint inhibitors?
Is PLC component loss a biomarker for immunotherapy resistance?

Common questions

What is the peptide-loading complex?

The PLC is a group of proteins in every cell that loads small peptide fragments onto MHC-I molecules. These loaded MHC-I molecules display the peptides on the cell surface like flags, allowing the immune system to check whether the cell is normal or abnormal (like a cancer cell). When tumors shut down the PLC, they become invisible to immune attacks.

Why do some cancers resist immunotherapy?

One major reason is that tumors reduce their PLC components, which decreases MHC-I on their surface. Without MHC-I displaying tumor peptides, T cells cannot recognize the cancer. This is why some patients do not respond to checkpoint inhibitors or CAR-T therapy—their tumors have become "invisible" to the immune system.

Read the original research

The potential applications of peptide-loading complex in cancer treatment.

Frontiers in immunology, 16, 1526137

View on PubMed ↗Publisher’s paper ↗

Citation

Song, Zhidu; Tao, Ying; You, Jiaxin. (2025). The potential applications of peptide-loading complex in cancer treatment.. Frontiers in immunology, 16, 1526137. https://doi.org/10.3389/fimmu.2025.1526137